Switch to:
More From Other Websites
AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink Feb 23 2017
In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs Feb 23 2017
Amgen Signs Value-Based Deal for Enbrel Feb 23 2017
Big Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs Feb 23 2017
Amgen Gets EU Nod for Monthly Repatha Dose Feb 22 2017
The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda Feb 22 2017
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising Feb 22 2017
Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery... Feb 21 2017
Top Research Reports for Amgen, Bank of America, and Proctor & Gamble Feb 21 2017
How Amgen’s Kyprolis Is Positioned in Second-Line Multiple Myeloma Segment Feb 21 2017
Roche Sues Amgen Over Avastin Biosimilar Drug Feb 20 2017
Repatha Represents a Solid Growth Opportunity for Amgen in 2017 Feb 20 2017
Amgen’s Neutropenia Drugs May See Falling Revenues in 2017 Feb 20 2017
Enbrel Strengthens Its Position in Rheumatology and Dermatology Segments Feb 20 2017
AMGEN INC Financials Feb 18 2017
Mylan's Proposed Biosimailar for Cancer Under Review in U.S. Feb 17 2017
Amgen Is Managing the Life Cycle of Its Mature Nephrology Drugs in 2017 Feb 17 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK